• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Rabbit anti-Human PODXL Polyclonal Antibody

The antibody against PODXL was raised in Rabbit using the recombinant fusion protein containing a sequence corresponding to amino acids 287-526 of human PODXL (NP_005388.2) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, ELISA.

ADA-10904A

The antibody against PODXL was raised in Rabbit using the recombinant fusion protein containing a sequence corresponding to amino acids 287-526 of human PODXL (NP_005388.2) as the immunogen. The polyclonal antibody exists as a isotype IgG, by affinity purification. This antibody has been validated on WB, ELISA.

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ADA-10904A ClonalityPolyclonal
Host SpeciesRabbitTarget NamePODXL
Target SynonymsPC; PDX; PCLP; Gp200; gp135; PCLP-1; PODXL1; PODXLFormLiquid
Species ReactivityHuman, MouseIsotypeIgG
Storage Buffer50% Glycerol, PBS with 0.02% sodium azide, pH7.3.Purification MethodAffinity purification
Positive SamplesHeLa, Mouse heart, Mouse kidney, 293T, HepG2, HT-1080, Mouse lung, SW480ApplicationELISA, WB

Immunogen Information


Immunogen DescriptionRecombinant fusion protein containing a sequence corresponding to amino acids 287-526 of human PODXL (NP_005388.2).Target SpeciesHuman
Uniprot IDO00592Immunogen Sequence
Background Information
  • Uniprot Id

    O00592

  • Target Species

    Human

  • Target Name

    PODXL

  • Target Full Name

    Podocalyxin

  • Target Function

    Involved in the regulation of both adhesion and cell morphology and cancer progression. Functions as an anti-adhesive molecule that maintains an open filtration pathway between neighboring foot processes in the podocyte by charge repulsion. Acts as a pro-adhesive molecule, enhancing the adherence of cells to immobilized ligands, increasing the rate of migration and cell-cell contacts in an integrin-dependent manner. Induces the formation of apical actin-dependent microvilli. Involved in the formation of a preapical plasma membrane subdomain to set up initial epithelial polarization and the apical lumen formation during renal tubulogenesis. Plays a role in cancer development and aggressiveness by inducing cell migration and invasion through its interaction with the actin-binding protein EZR. Affects EZR-dependent signaling events, leading to increased activities of the MAPK and PI3K pathways in cancer cells.

  • Target Subcellular Location

    Apical cell membrane. Cell projection, lamellipodium. Cell projection, filopodium. Cell projection, ruffle. Cell projection, microvillus. Membrane raft. Membrane; Single-pass type I membrane protein.

  • Target Protein Families

    Podocalyxin family

  • Target Tissue Specificity

    Glomerular epithelium cell (podocyte).

  • Target Research Area

    Cancer

  • Target Synonyms

    GCTM-2 antigen; Gp2; Gp200; MGC138240; PC; PCLP; PCLP-1; PCLP1; Pcx; Podocalyxin; Podocalyxin like; Podocalyxin like protein; Podocalyxin-like protein 1; Podxl; PODXL_HUMAN

  • Target Background

    This gene encodes a member of the sialomucin protein family. The encoded protein was originally identified as an important component of glomerular podocytes. Podocytes are highly differentiated epithelial cells with interdigitating foot processes covering the outer aspect of the glomerular basement membrane. Other biological activities of the encoded protein include: binding in a membrane protein complex with Na+/H+ exchanger regulatory factor to intracellular cytoskeletal elements, playing a role in hematopoetic cell differentiation, and being expressed in vascular endothelium cells and binding to L-selectin.

Inquire Rabbit anti-Human PODXL Polyclonal Antibody Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification